Company: BLRX
Filing Date: 2025-04-11
Form Type: 424B5
Source: 0001178913-25-001282
Chunk: 1

Company: BioLineRx Ltd.
Filing Date: 2025-04-11
Form: 424B5
Chunk 1
---
 of Form F-3, in no event will we sell securities in public primary
      offerings on Form F-3 with a value exceeding one-third of our public float (as defined by General Instruction I.B.5) in any 12 calendar month period so long as our public float remains below $75.0 million.

Our ADSs are listed on Nasdaq under the symbol “BLRX”. On April 10, 2025, the closing price of our ADSs on Nasdaq was $2.43 per ADS. Our ordinary shares also trade on the Tel Aviv Stock Exchange, or the TASE, under the symbol “BLRX”. On April 10, 2025, the last reported sale price of our ordinary shares on the TASE was NIS 0.017 or $0.005 per share (based on the exchange rate reported by the Bank of Israel on the same day).

Investing in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well as the information
      incorporated herein and therein by reference carefully before you make your investment decision. See “Risk Factors” beginning on page S-5 of the ATM Prospectus and on page S-1 of the accompanying prospectus, and the risk factors described in other
      documents incorporated by reference therein, to read about the factors you should consider before investing in our securities.

Neither the Securities and Exchange Commission, the Israel Securities Authority nor any state or other foreign securities commission has approved or
        disapproved of these securities or determined if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

#### H.C. Wainwright & Co.
<div align='center'>**The date of this prospectus supplement is April 11, 2025.**</div>